IN2015KN00076A - - Google Patents

Info

Publication number
IN2015KN00076A
IN2015KN00076A IN76KON2015A IN2015KN00076A IN 2015KN00076 A IN2015KN00076 A IN 2015KN00076A IN 76KON2015 A IN76KON2015 A IN 76KON2015A IN 2015KN00076 A IN2015KN00076 A IN 2015KN00076A
Authority
IN
India
Prior art keywords
diabetes
functional groups
compounds
docosahexaenoate
eicosapentaenoate
Prior art date
Application number
Inventor
Banavara L Mylari
Frank C Sciavolino
Original Assignee
Thetis Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/841,970 external-priority patent/US8765811B2/en
Application filed by Thetis Pharmaceuticals Llc filed Critical Thetis Pharmaceuticals Llc
Publication of IN2015KN00076A publication Critical patent/IN2015KN00076A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C277/00—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C277/08—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups of substituted guanidines

Abstract

Provided herein are tri-salt compounds comprising a compound having two acidic functional groups and one basic functional groups (e.g., aspartate or glutamate), metformin, and polyunsaturated fatty acids, such as eicosapentaenoate or docosahexaenoate. The salts can be used in the treatment of diabetes, diabetes with concomitant dyslipidemia (e.g. , high triglycerides) and diabetes exacerbated cardiovascular complications, such as cardiac arrhythmia, cardiac ischemia, myocardial infarction, cardiomyopathy, and stroke. The compounds of this invention are also useful in treating obesity.
IN76KON2015 2012-07-10 2013-07-10 IN2015KN00076A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261669763P 2012-07-10 2012-07-10
US201261670368P 2012-07-11 2012-07-11
US201261670376P 2012-07-11 2012-07-11
US13/841,970 US8765811B2 (en) 2012-07-10 2013-03-15 Tri-salt form of metformin
PCT/US2013/049984 WO2014011814A1 (en) 2012-07-10 2013-07-10 Tri-salt form of metformin

Publications (1)

Publication Number Publication Date
IN2015KN00076A true IN2015KN00076A (en) 2015-07-31

Family

ID=49916541

Family Applications (1)

Application Number Title Priority Date Filing Date
IN76KON2015 IN2015KN00076A (en) 2012-07-10 2013-07-10

Country Status (12)

Country Link
EP (1) EP2872483A4 (en)
JP (1) JP2015523382A (en)
KR (1) KR20150036235A (en)
CN (1) CN104684889A (en)
AU (1) AU2013290168A1 (en)
BR (1) BR112015000368A2 (en)
CA (1) CA2878819A1 (en)
IL (1) IL236613A0 (en)
IN (1) IN2015KN00076A (en)
MX (1) MX2015000408A (en)
WO (1) WO2014011814A1 (en)
ZA (1) ZA201500274B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014124141A1 (en) * 2013-02-07 2014-08-14 Mylari Banavara L Metformin derivatives for treating diabetes
CA2947741A1 (en) 2014-05-05 2015-11-12 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
BR112016029476A2 (en) * 2014-06-18 2017-08-22 Thetis Pharmaceuticals Llc mineral amino acid complexes of active agents
US20170119841A1 (en) * 2015-11-04 2017-05-04 Thetis Pharmaceuticals Llc Amino acid salts of unsaturated fatty acids
KR102437682B1 (en) 2016-06-03 2022-08-29 테티스 파마수티컬스 엘엘씨 Compositions and methods for salts of specialized pre-resolving mediators
US10471963B2 (en) 2017-04-07 2019-11-12 TuSimple System and method for transitioning between an autonomous and manual driving mode based on detection of a drivers capacity to control a vehicle
US10737695B2 (en) 2017-07-01 2020-08-11 Tusimple, Inc. System and method for adaptive cruise control for low speed following
CN113105367B (en) * 2021-03-30 2022-08-02 广州大学 Metformin salt and preparation method and application thereof
CN114349665B (en) * 2021-11-30 2023-06-09 潍坊博创国际生物医药研究院 Metformin pyroglutamic acid crystal and preparation method and application thereof
CN116999398A (en) * 2022-06-30 2023-11-07 山东海赜生物科技有限公司 An oral composition

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE261935T1 (en) * 1997-12-08 2004-04-15 Bristol Myers Squibb Co NEW METFORMIN SALTS AND METHODS
FR2774591B1 (en) * 1998-02-12 2000-05-05 Lipha PHARMACEUTICAL COMPOSITION COMPRISING THE ASSOCIATION OF METFORMIN AND FIBRATE AND THE USE THEREOF FOR THE PREPARATION OF MEDICINES FOR REDUCING HYPERGLYCEMIA
WO2002012177A1 (en) * 2000-08-03 2002-02-14 Igor Anatolievich Pomytkin Composition of metformin with succinic acid or salts thereof and method for treating diabetes
PL377614A1 (en) * 2003-03-18 2006-02-06 Novartis Ag Compositions comprising fatty acids and amino acids
EP1591114A1 (en) * 2004-03-12 2005-11-02 Fournier Laboratories Ireland Limited Use of metformin and orlistat for the treatment or prevention of obesity
JP5292404B2 (en) * 2007-09-21 2013-09-18 ハンオル バイオファーマ カンパニー，リミテッド Dicarboxylate of N, N-dimethylimidodicarbonimidic acid diamide, process for producing the same, and pharmaceutical composition thereof
DK2229158T3 (en) * 2007-12-20 2016-12-12 Fertin Pharma As Compressed chewing gum tablet
WO2009151116A1 (en) * 2008-06-13 2009-12-17 持田製薬株式会社 Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis
CA2759176C (en) * 2009-04-29 2016-03-15 Amarin Corporation Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
JP2013540156A (en) * 2010-10-19 2013-10-31 エルセリクス セラピューティクス インコーポレイテッド Chemosensory receptor ligand based therapy
US8796338B2 (en) * 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US20120178813A1 (en) * 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
WO2014124141A1 (en) * 2013-02-07 2014-08-14 Mylari Banavara L Metformin derivatives for treating diabetes

Also Published As

Publication number Publication date
ZA201500274B (en) 2017-10-25
CA2878819A1 (en) 2014-01-16
JP2015523382A (en) 2015-08-13
MX2015000408A (en) 2015-07-14
EP2872483A4 (en) 2016-03-16
KR20150036235A (en) 2015-04-07
AU2013290168A1 (en) 2015-02-05
WO2014011814A1 (en) 2014-01-16
CN104684889A (en) 2015-06-03
BR112015000368A2 (en) 2017-06-27
IL236613A0 (en) 2015-02-26
EP2872483A1 (en) 2015-05-20

Similar Documents

Publication Publication Date Title
IN2015KN00076A (en)
EP2623586A3 (en) Compositions and methods for surface treatment with lipases
PH12014502795A1 (en) Production of long chain polyunsaturated fatty acids in plant cells
EA201390341A1 (en) ADSORPTION OF IMMUNOTE POTENTIATORS ON INSOLUBLE SALTS OF METALS
BR112013017383A2 (en) method, coating composition and its uses
BR112017018187A2 (en) compositions comprising combinations of organic acids
ZA201900146B (en) Lysine: hydrochloride synthetic acid compositions as alternatives to conventional acids in the oil and gas industry
IN2015DN03281A (en)
WO2013049519A3 (en) Compositions, kits and methods for nutritional supplementation with twelve carbon chain fatty acids and twelve carbon chain acylglycerols
AR087432A1 (en) PROCEDURE FOR PREPARATION OF AMINO-ACIDS OR ESTERS THAT INCLUDES A STAGE OF METATESIS
TN2014000133A1 (en) Environmentally friendly tanning composition
EP2776117A4 (en) Acute myocardial infarction treatment by electrical stimulation of the thoracic aorta
BR112017018172A2 (en) compositions comprising combinations of organic acids
CR20120561A (en) COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TUMOR TREATMENT
MX2015007535A (en) Application tool.
WO2012122346A3 (en) Beneficial thermo-chemical treatment of kaolin with ammonium polyphosphate
RS60161B1 (en) Biologically active food additive for treatment of myocardial ischemia
FR3005496B3 (en) OVEN PLATE PRODUCED IN THE FORM OF A PLATE TO BE INSERTED FOR OVENS, ESPECIALLY STORAGE OVENS.
Nuotio et al. Etsivä nettityö
EP2872555A4 (en) Surfactant composition with low dynamic surface tension
MX2017002666A (en) Washing additive.
MX2016000969A (en) Manganese carboxylates for peroxygen activation.
WO2015044923A3 (en) Nucleic acids binding specifically to human factor ix/ixa, and uses thereof
TH111894B (en) Shoes
TH116179B (en) Unsaturated acids for the prevention of color fading derived from the following sources. Naturally used in beverage products.